A group of 30 experts in Latin America participated in a study to see if local practices matched international guidelines for hereditary angioedema. They reached a consensus on several key areas, including the use of specific biochemical tests for diagnosis and the use of targeted long-term prevention therapies like pdC1-INH, lanadelumab, and berotralstat. They also agreed on the importance of routine monitoring and managing special patient groups.
While the experts agreed on these treatment goals, they also identified significant hurdles to making these treatments available to everyone. Specifically, 63 percent of the experts reported that high costs and frequent interruptions in the supply of medicine were major barriers. Another 27 percent of experts noted that the general availability of medicine was also a challenge.
It is important to note that these findings are based on the opinions and reports of a small group of experts. The data were not independently verified against official health system records or insurance data. Because these results reflect expert perceptions rather than a broad audit of the healthcare system, they should be viewed as a guide for identifying where improvements are needed in care.
